|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Chesapeake Urology Research Associates Sanofi-Aventis |
|---|---|
| Information provided by: | Chesapeake Urology Research Associates |
| ClinicalTrials.gov Identifier: | NCT00893113 |
Purpose
The purpose of this study is to assess the effect of Alfuzosin in treating Erectile Dysfunction in Men that have lower urinary tract symptoms.
| Condition | Intervention | Phase |
|---|---|---|
|
Erectile Dysfunction Lower Urinary Tract Symptoms |
Drug: Alfuzosin |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
| Official Title: | A Phase 3, Double Blind, Placebo-COntrolled, Crossover Study to Evaluate the Efficacy of Alfuzosin in Treating Men With ED and Mild LUTS. |
| Estimated Enrollment: | 60 |
| Study Start Date: | May 2009 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo: Placebo Comparator |
Drug: Alfuzosin
10 mg once daily
Drug: Alfuzosin
10 mg once daily
|
| Alfuzosin: Experimental |
Drug: Alfuzosin
10 mg once daily
|
Eligibility| Ages Eligible for Study: | 30 Years to 60 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Mary O'Conor, CCRC | 443-471-5740 | moconor@cua.md |
| Contact: Virginia Michaels, CRC | 410-760-9400 | vmichaels@cua.md |
| United States, Maryland | |
| Chesapeake Urology Research Associates | |
| Baltimore, Maryland, United States, 21204 | |
| Chesapeake Urology Research Associates | |
| Glen Burnie, Maryland, United States, 21061 | |
| Chesapeake Urology Research Associates | |
| Bel Air, Maryland, United States, 21014 | |
| Chesapeake Urology Research Associates | |
| Towson, Maryland, United States, 21204 | |
| Chesapeake Urology Research Associates | |
| Towson, Maryland, United States, 21204 | |
| Chesapeake Urology Research Associates | |
| Baltimore, Maryland, United States, 21207 | |
| Principal Investigator: | Ronald F Tutrone, MD | Chesapeake Urology Research Associates |
More Information
| Responsible Party: | Chesapeake Urology Research Associates ( Ronald Tutrone, MD ) |
| Study ID Numbers: | CURA-RT-002 |
| Study First Received: | April 8, 2009 |
| Last Updated: | May 4, 2009 |
| ClinicalTrials.gov Identifier: | NCT00893113 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Sexual Dysfunctions, Psychological Neurotransmitter Agents Alfuzosin Sexual Dysfunction, Physiological Adrenergic Agents Mental Disorders |
Adrenergic Antagonists Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents Genital Diseases, Male Erectile Dysfunction |
|
Sexual Dysfunctions, Psychological Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents Genital Diseases, Male |
Sexual and Gender Disorders Pharmacologic Actions Sexual Dysfunction, Physiological Alfuzosin Mental Disorders Therapeutic Uses Adrenergic Antagonists Erectile Dysfunction |
